Ardelyx Corp (ARDX) - Long-Term Debt to Capital Coefficient
Innovative kidney and gastrointestinal therapies from Ardelyx, Inc. (ARDX) are currently aggressively capturing the market, establishing a long-term consumption cycle. This chart of the current market value on GURU.Markets, where the indicator stands at 1.79, helps track this progress. Ardelyx, Inc. (ARDX) relies on breakthrough molecules that create strong customer loyalty, although high promotion and R&D expenses are currently constraining stable cash flow.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_ARDX_-_Ardelyx-Inc._-_Long-Term-Debt-to-Capital "ARDX: Ardelyx Long-Term Debt to Capital 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Ardelyx, Inc. (ARDX)
As Ardelyx, Inc. (ARDX) expands partnerships with nephrologists to implement metabolic disorder therapies, the company requires stable funding for long-term projects. This ratio compares loans with maturities exceeding one year against equity, determining the degree of financial leverage and resilience to crises. By analyzing the long-term debt-to-equity ratio trend, an investor assesses the balance between debt load and the business's capital security.